Further, reverse translational studies demonstrated that mice bearing CXCL13-ablated tumors were resistant to ICB, whereas loss of ARID1A improved sensitivity to anti-PD-1 therapy in a murine model of bladder cancer. Here, ARID1A is linked to urinary bladder cancer.